Primary Pulmonary Lymphoepithelioma-Like Carcinoma Response Favorably To Nivolumab: A Case Report

Zhi-Xin Qiu1
Ping Zhou2
Ke Wang1
1Department of Respiratory and Critical Care Medicine, West China Hospital, Sichuan University, Chengdu, People’s Republic of China; 2Department of Pathology, West China Hospital, Sichuan University, Chengdu, People’s Republic of China

Objectives: Lymphoepithelioma-like carcinoma (LELC) is a rare subtype of non-small cell lung cancer (NSCLC). No clinical trials have been performed, and no course of treatment for LELC has been established because of its rarity. This study presents a patient with primary pulmonary LELC, who was treated with nivolumab, and responded favorably.

Materials and methods: A patient with primary pulmonary LELC was treated using nivolumab.

Result: The patient responded well to immunotherapy with nivolumab. After five cycles of the nivolumab, the size of the tumor and the lesions of the liver became smaller. A blood test showed that CYFRA21-1 and NSE had dramatically decreased from before, especially the CYFRA21-1.

Conclusion: EBV-positive pulmonary LELC with high expression of PD-L1 may derive a benefit from PD-1/PD-L1 blockade.

Keywords: LELC, NSCLC, nivolumab, PD-L1

Introduction

Lymphoepithelioma-like carcinoma (LELC), which has similar morphology with undifferentiated nasopharyngeal carcinoma (NPC), is a rare subtype of non-small cell lung cancer (NSCLC), and has often been identified in young non-smokers. The incidence of LELC is ~0.7% of all NSCLC and it was first described by Begin et al in 1987. LELC is usually associated with Epstein-Barr virus (EBV) infection, and has been documented with specific ethnic and regional preferences, especially patients from Asia, such as Guangdong Province, Hong Kong, and Taiwan in China.

Owing to its rarity, no clinical trials have been performed, and no course of treatment for LELC has been established. Only case reports and retrospective series have been reported. Treatment at advanced stages has usually relied on multimodal therapy, including chemotherapy and radiotherapy. In recent years, significant advances have been made in cancer immunotherapy. Here, we present a patient with LELC of the lung, who was treated with nivolumab, responding favorably.

Case Presentation

A 56-year-old never smoking woman was admitted to our Lung Cancer Center with no symptoms, but a big mass was found in the left lower lobe (Computed tomography (CT) of the chest) through annual healthy check-up. She denied hepatitis,
tuberculosis, or other infectious disease, and had no history of smoking, drinking, allergies, or surgery. There was no obvious change in body weight.

An enhanced CT of the chest, whole abdomen, brain, and nasopharyngeal and whole body bone scan were arranged. The enhanced CT of the chest showed a bulky soft tissue mass in the left lower lobe with lobulated, burr sign, and the largest cross-section size was about 6.4×6.0 cm. Furthermore, the left lung door and mediastinal lymph nodes showed enlargement. There were no trachea bronchial stenosis and no pericardial or pleural effusion (Figures 1A1, A2, B1, and B2). The enhanced CT of the whole abdomen showed a kind of circular low density shadow of 4.1×3.6 cm in the liver (Figure 1C). The brain and nasopharyngeal enhanced CT and the whole body bone scan were roughly normal except some focal ischemia, deputy nose, and hypertrophy of bilateral inferior turbinate (Figures 1D–F). Serum tumor markers indicated cell keratin fragments antigen 21–1 (CYFRA21-1) and neural specificity enolase (NSE) were higher than the normal values (10.38 ng/mL vs <3 ng/mL and 22.62 ng/mL vs <15 ng/mL, respectively). Carcinoembryonic antigen (CEA), serum carbohydrate antigen 125, 19–9, 15–3, and 72–4 (CA125, CA19-9, CA15-3, and CA72-4) were all negative. Other abnormal blood test results including heat shock protein 90α (HSP90α) and erythrocyte sedimentation (ESR), especially EBV-EA-IgG was 158.14 RU/mL which was almost eight times higher than normal value.

In order to define the diagnosis, fiber optic bronchoscope (FOB) and percutaneous lung biopsy were performed. All levels of the bronchial lumen biopsy were normal through the FOB, and the biopsy showed only chronic inflammation. However, percutaneous lung biopsy prompted lymphoepithelioma-like carcinoma combined with the results of hematoxylin-eosin (HE) and immunohistochemical (IHC) staining. IHC staining demonstrated PCK (+), P40 (+), CK5/6 (+), EBER1/2-ISH (+), CK7 (-), TTF-1 (-), and PD-L1 (+, positive proportion about 80%, antibody SP142, ZSGB-BIO Company) (Figure 2). The findings from next generation sequencing (NGS) were negative for mutations in EGFR, KRAS, and BRAF and negative for rearrangements in ALK and ROS1. Then we diagnosed left lower lobe lymphoepithelioma-like carcinoma invading the pericardium and descending aorta, with metastasis of mediastinal lymph nodes and liver (cT4N2M1b, stage IVA).

The first treatment regimen was paclitaxel (190 mg) plus carboplatin (550 mg). After two cycles, we evaluated the curative effect according to enhanced CT of the chest and whole abdomen, and we found the size of tumor became larger (Figures 3A1 and A2) and the lesions of liver became more broader than before (Figures 3B1–B4, evaluation result was SD (according to RECIST 1.1)). We evaluated again after four cycles of chemotherapy, and found the CT imaging demonstrated significant progression of disease (Figure 4, evaluation result was PD). After consulting with the patient and considering the high expression of
PD-L1, we decided to stop the chemotherapy and began to use nivolumab (Opdivo; Bristol-Myers Squibb, New York, NY). Subsequently, the patient was administered nivolumab 3 mg/kg every 14 days. After two cycles, we evaluated the curative effect again, and to our surprise the size of the mass had reduced significantly (Figures 5A1 and 5A2, evaluation result was PR), and there was no metastasis in the brain (Figure 5B). After five cycles of nivolumab, the size of the tumor and the lesions of the liver became even smaller (Figure 6, evaluation result was PR). At the same time, we performed the blood tests again and found that the values of CYFRA21-1 and NSE dramatically decreased compared to before, especially the CYFRA21-1 (Figure 7).

So far, this patient has finished six cycles of treatment of nivolumab and there have been no obvious side-effects during the treatment process except an occasional mild cough. Meantime, the hormone level of the thyroid and cortisol have remained roughly normal.
Discussion

We have described the diagnosis and treatment process of a patient with stage IVA primary pulmonary LELC in the present case. A case report of three patients with LELC treated with PD-1 antibody was reported recently. Among these cases, two of them with nivolumab did not result in an objective response, but with rapidly progressing disease.\textsuperscript{10,11} Only one patient experienced a partial response to atezolizumab for six cycles that lasted 4 months.\textsuperscript{12} To the best of our knowledge, this case is the first report of primary pulmonary LELC responding favorably to nivolumab. Our patient experienced a partial response to nivolumab for six cycles that lasted 5 months. During this time, her tumor burden had decreased significantly.

Pulmonary LELC is a rare malignancy, estimated to represent 0.15\% to 3.6\% of all lung malignancies, and is usually associated with EBV infection, which, at one point, was even thought to be the main etiology of LELC.\textsuperscript{12,13} LELC is more commonly found in Asia, and most cases have been reported in Southeast Asia, specifically Hong Kong, Taiwan, and Guangdong.\textsuperscript{7} Our patient came from southwest of China, and IHC showed a positive EBER1/2-ISH. Furthermore, this patient had the same clinical and radiographic features with literature reported before, such as being a middle-aged women with no-smoking history, the large size of tumor at the central lesions, and the values of serum tumor markers of CYFRA21-1 and NSE were usually high.\textsuperscript{14}

Immune checkpoint inhibitors, targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4) and programmed death-1 (PD-1), are a recent addition to the treatment arsenal against different types of advanced cancers, including NSCLC.\textsuperscript{10,15} Nivolumab and pembrolizumab, as anti-PD-1 antibodies, have shown survival benefits over standard second-line chemotherapy for advanced NSCLC, and are approved for treatment of unresectable NSCLC after progression on platinum containing chemotherapy, or appropriate molecular-targeted therapy in patients with EGFR-sensitizing mutations or ALK translocations.\textsuperscript{16,17} The mechanism of immune checkpoint blockade in pulmonary LELC remains unclear, but activity of immune checkpoint inhibitors observed in other virus-associated cancers warrants further evaluation of this new class of cancer therapeutics in patients with pulmonary LELC. El-Khoueiry et al\textsuperscript{18} indicated that the objective response rate (ORR) in patients with virus-associated hepatocellular carcinoma (HCC) treated with nivolumab was 32\%, which was higher than in uninfected patients with HCC (ORR, 15\%). Additionally, the use of pembrolizumab for the treatment of recurrent or metastatic squamous cell carcinoma led to a higher ORR in patients with human papillomavirus (HPV)-positive tumor (ORR=25\%), compared to those with HPV-negative (ORR=14\%).\textsuperscript{19} Similarly, in patients with Merkel-cell carcinoma, a skin cancer linked to the Merkel-cell polyomavirus, the ORR was 56\% after treatment with
Several studies reported that tumors expressing PD-L1 are more likely to respond to PD-1/PD-L1 blockade.\textsuperscript{17,21–23} Our patient had high expression of PD-L1 with a positive rate about 80\%, consistent with previously research. However, PD-L1 expression on tumor cells was predictive of treatment outcomes, including ORR and OS in patients with non-squamous NSCLC, but not in those with squamous NSCLC in two phase III trials of nivolumab in NSCLC.\textsuperscript{10,16,24} In summary, the findings below provide a rationale to treat patients with pulmonary LELC with immune checkpoint therapy.

**Conclusion**

We have reported the case of an Asian patient with EBV-positive primary pulmonary LELC. Our patient responded well to immunotherapy with nivolumab. Although the effectiveness of checkpoint inhibition in pulmonary LELC will be difficult to assess owing to the low incidence rate, the findings from our present case report indicate that EBV-positive pulmonary LELC with high expression of PD-L1 may derive benefit from a PD-1/ PD-L1 blockade. However, specific trials of immunotherapy for rare lung cancer cases are still warranted.

**Consent Statement**

Written and informed consent has been provided by the patient to have the case details and any accompanying images published.

The director of West China Hospital Weimin Li clarified: The manuscript of “Primary Pulmonary Lymphoepithelioma-like Carcinoma Response Favorably to Nivolumab: A Case Report” by Dr. Qiu et al has been informed for publication. All case details and any accompanying images have been checked and approved.

**Funding**

This work was supported by the National Science Foundation of China (81700095, 81870034).

**Disclosure**

The authors report no conflicts of interest in this work.

**References**


